Metselaar, Josbert http://orcid.org/0000-0003-1360-0112
Lammers, Twan
Boquoi, Amelie
Fenk, Roland
Testaquadra, Fabio
Schemionek, Mirle
Kiessling, Fabian
Isfort, Susanne
Wilop, Stefan
Crysandt, Martina
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (GRK2375)
FP7 Ideas: European Research Council (Consolidator Grant 864121)
RWTH Aachen University
Article History
Accepted: 23 November 2022
First Online: 2 January 2023
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Independent Ethics Committee at the Medical Faculty of RWTH Aachen University. Informed consent to participate was obtained from all individual participants included in the study.
: Consent to publish has been received from all study participants.
: Josbert Metselaar declares a honorarium from Enceladus Pharmaceuticals; Amelie Boquoi has received speaker honoraria by BMS, AbbVie and Janssen, travel support by Takeda, and has served on advisory boards for GSK, Sanofi, Janssen, Takeda, Amgen, and BMS; Susanne Isfort has received consultant honoraria from Novartis, Pfizer, Incyte and travel support from Pfizer, Novartis, Hexal, Roche, Alexion, Mundipharma; Martina Crysandt has received speaker and consultant honoraria from Astra Zeneca, Novartis and travel support from Pfizer.